Boliven PRO is more than just patent search

  • Build and save lists using the powerful Lists feature
  • Analyze and download your search results
  • Share patent search results with your clients

Patents »

US6451578: Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use


Filing Information

Inventor(s) John N. Simons · Tami J. Pilot-Matias · George J. Dawson · George G. Schlauder · Suresh M. Desai · Thomas P. Leary · Anthony Scott Muerhoff · James Carl Erker · Sheri L. Buijk · Isa K. Mushahwar ·
Assignee(s) Abbott Laboratories ·
Attorney/Agent(s) Cheryl L. Becker · Dianne Casuto ·
Primary Examiner Donna Wortman ·
Application Number US8469260
Filing date 06/06/1995
Issue date 09/17/2002
Predicted expiration date 02/14/2014
U.S. Classifications 435/235.1  · 435/5  · 436/820  ·
International Classifications --
Kind CodeB1
International Classifications 4241841 · 4242041 · 4242251 · 4352351 · 435325 · 435 5 · 514 1 · 530350 · 436820 ·
Related U.S. Application DataThis application is a divisional of U.S. Ser. No. 08/424,550 filed Jun. 5, 1995 which is a continuation-in-part application of U.S. Ser. No. 08/377,557 filed Jan. 30, 1995, abandoned which is a continuation-in-part of U.S. Ser. No. 08/344,185 filed Nov. 23, 1994, abandoned, and U.S. Ser. No. 08/344,190 filed Nov. 23, 1994, abandoned, which are each continuation-in-part applications of Ser. No. 08/283,314 filed Jul. 29, 1994, abandoned, which is a continuation-in-part application of U.S. Ser. No. 08/242,654, filed May 13, 1994, abandoned, which is a continuation-in-part application of U.S. Ser. No. 08/196,030 filed Feb. 14, 1994, abandoned, all of which enjoy common ownership and each of which is incorporated herein by reference.
2 Claims, 49 Drawings


Hepatitis GB Virus (HGBV) nucleic acid and amino acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences, HGBV immunogenic particles, and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV nucleic acid or amino acid sequences.

Independent Claims | See all claims (2)

  1. 1. Partially purified hepatitis GB virus (HGBV), comprising an HGVB antigen, wherein said HGBV antigen (a) comprises a sequence of at least 8 contiguous amino acids, (b) is encoded by a positive stranded RNA viral genome wherein said viral genome encodes a polyprotein represented by SEQUENCE I.D. NO 387 and (c) exhibits no immunoreactivity with an antibody that specifically binds to hepatitis C virus.
  2. 2. Partially purified hepatitis GB virus (HGBV) comprising an HGBV antigen, wherein said HGBV antigen has a contiguous sequence of at least 15 amino acids, and said HGBV antigen exhibits an amino acid sequence represented by SEQUENCE I.D. NO. 387.

References Cited

U.S. Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
US4743535 Miles Inc. Carrico May 1988
US4876187 Meiogenics, Inc. Duck et al. Oct 1989
US5275947 The Research Foundation for Microbial Disease of Osaka University Arima et al. Jan 1994
US5399346 The United States of America as represented by the Department of Health and Human Services Anderson et al. Mar 1995
US5527669 Hoffmann-La Roche Inc. Resnick et al. Jun 1996
US5576302 ISIS Pharmaceuticals, Inc. Cook et al. Nov 1996
US5766840 Genelabs Technologies, Inc. Kim et al. Jun 1998

Foreign Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
WO199000597*Jan 1990
WO199000597Jan 1990
WO199408002Apr 1994
WO199418217Aug 1994
WO199532290Nov 1995
WO199532291Nov 1995
WO199532292Nov 1995
WO199506266May 1996
* cited by examiner

Other Publications

Whittington et al., “Comparison of Infectivity of Human Non-A/Non-B Hepatitis and the GB Hepatitis Agent in Marmosets”, Viral and Immunological Diseases in Nonhuman Primates (Kalter, ed.) Alan R. Liss, NY, 1983, pp. 221-224.*
Karayiannis et al., “Studies of GB Hepatitis Agent in Tamarins”, Hepatology 9, 186-192 (1989).*
S. K. Kuwada et al.,
A. S. Muerhoff et al.,
S. Vijayasarathy,
P. Tijssen, “Practice and Theory of Enzyme Immunoassays”, Elsevier, Amsterdam, pp. 333-340 (1985).
A. Takamizawa et al.,
T. Gura, “Antisense Has Growing Pains”,
D. Brown, “Gene Therapy ‘Oversold’ by Researchers, Journalists”,
Choo et al.,
Okamoto et al., “Polyprotein precursor—hepatitis C virus”, EMBL Sequence Accession No. S40770, Submitted Mar. 1992.
Okamoto et al.,
U.S. application No. 08/389,886, Kim et al., filed Jan. 15, 1995.
U.S. application No. 08/357,509, Kim et al., filed Dec. 16, 1994.
U.S. application No. 08/344,271, Fry et al., filed Nov. 23, 1994.
U.S. application No. 08/329,729, Kim et al., filed Oct. 26, 1994.
U.S. application No. 08/285,558, Kim et al., filed Aug. 3, 1994.
U.S. application No. 08/246,985, Kim et al., filed May 26, 1994.
T. Peters et al., Frequency of Hepatitis C in Acute Post-Transfusion Hepatitis After Open-Heart Surgery: A Prospective Study in 1,476 Patients,
R. Purcell, The Discovery of the Hepatitis Viruses,
G. Dawson et al., Solid-phase enzyme-linked immunosorbent assay for hepatitis E virus IgG and IgM antibodies utilizing recombinant antigens and synthetic peptides,
P. Yarbough et al., Hepatitis E Virus: Identification of Type-Common Epitopes,
H. Alter et al., Detection of Antibody to Hepatitis C Virus in Prospectively Followed Transfusion Recipients with Acute and Chronic Non-A, Non-B Hepatitis,
M. Alter et al., Risk Factors for Acute Non-A, Non-B Hepatitis in the United States and Association With Hepatitis C Virus Infection,
J. Dienstag, Hepatitis Non-A, Non-B: C at Last,
G. Reyes et al., Isolation of a cDNA from the Virus Responsible for Enterically Transmitted Non-A, Non-B Hepatitis,
G. Kuo et al., An Assay for Circulating Antibodies to a Major Etiologic Virus of Human Non-A, Non-B Hepatitis,
A. Weiner et al., Detection of hepatitis C viral sequences in non-A, non-B hepatitis,
G. Schlauder et al., Viraemia in Egyptian children with hepatitis E virus infection,
N. Lisitsyn et at., Cloning the Differences Between Two Complex Genomes,
V. Thiers et al., Post-transfusional anti-HCV-negative non-A non-B hepatitis (II) serological and plymerase chain reaction analysis for hepatitis C and hepatitis B viruses,
Hepatitis C virus upstanding,
W. Parks et al., Attempted Isolation of Hepatitis Viruses in Marmosets,
A. Holmes et al., Specific Neutralization of Human Hepatitis Type A in Marmoset Monkeys,
P. Provost et al., Physical, Chemical and Morphologic Dimensions of Human Hepatitis A Virus Strain CR326 (38578),
Q. Choo et al., Isolation of a cDNA Clone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome,
J. Almeida et al., Morphology of the GB hepatitis agent,
F. Deinhardt et al., Studies on the Transmission of Human Viral Heptitis to Marmoset Monkeys,
J. Dienstag, Non-A, Non-B Hepatitis. II. Experimental Transmission, Putative Virus Agents and Markers, and Prevention,
F. Hollinger et al., Transfusion-Transmitted Viruses Study: Experimental Evidence for Two Non-A, Non-B Hepatitis Agents,
D. Bradley, Transmission, Etiology, and Pathogenesis of Viral Hepatitis Non-A, Non-B in Non-Human Primates,
F. Deinhardt et al., Hepatitis in marmosets,
S. Kalter, Comparison of Infectivity of Human Non-A/Non-B Hepatitis and the GB Hepatitis Agent in Marmosets,
E. Tabor et al., Transmission of Human Non-A, Non-B Hepatitis to Chimpanzees Following Failure to Transmit GB Agent Hepatitis,
D. Bradley et al., Posttransfusion Non-A, Non-B Hepatitis: Physicochemical Propterties of Two Distinct Agnets,
J. Dienstag, Virus-like particles and GB agent hepatitis,
P. Karayiannis et al., Studies of GB Hepatitis Agent in Tamarins,
J. Melnick, Classification of Hepatitis A Virus as Enterovirus Type 72 and of Hepatitis B Virus as Hepadnavirus Type 1,
W. Parks et al., Characterization of Marmoset Hepatitis Virus,
S. Feinstone et al., Hepatitis A: Detection by Immune Electron Microscopy of a Viruslike Antigen Associated with Acute Illness,
E. Tabor et al., Lack of Susceptibility of Marmosets to Human Non-A, Non-B Hepatitis,
E. Fagan et al., Toga Virus-Like Particles in Acute Liver Failure Attributed to Sporadic Non-A, Non-B Hepatitis and Recurrence After Liver Transplantation,
J. Dienstag, Virus particles in marmoset hepatitis,
F. Deinhardt et al., Hepatitis in Marmosets,
F. Deinhardt et al., The Mythology of Various Hepatitis A Virus Isolates,
M. Alter et al., The Natural History of Community-Acquired Hepatitis C in the United States,
R. Gibbs, Polymerase chain reaction techniques,
S. Friedman et al., The core element of the EcoRII methylase as defined by protease digestion and deletion analysis,
A. Rosenthal et al., Genomic walking and sequencing by oligo-cassette mediated polymerase chain reaction,
A. Akowitz, Protected endogenous retroviral sequences copurify with infectivity in experimental Creutzfeldt-Jakob disease,
Non-A, Non-B,
F. Hollinger, Non-A, Non-B Hepatitis Viruses,
J. Dienstag, Non-A, Non-B Hepatitis I. Recognition, Epidemiology, and Clinical Features,
J. Strauss et al., Structure and Function of the Flavivirus and Pestivirus Genomes,
H. Alter et al., Posttransfusion Hepatitis After Exclusion of Commercial and Hepatitis-B Antigen-Positive Donors,
H. Alter et al., Clinical and Serological Analysis of Transfusion-Associated Hepatitis,
S. Feinstone et al., Transfusion-Associated Hepatitis Not Due To Viral Hepatitis Type A or B,
J. Simons et al., Identification of two flavivirus-like genomes in the GB Hepatitis agent,
J. Simons et al., Isolation of novel virus-like sequences associated with human hepatitis,
G. Schlauder et al., Molecular and Serologic Analysis in the Transmission of the GB Hepatitis Agents,
M. Yoshiba et al., Detection of the GBV-C hepatitis virus genome in serum from patients with fulminant hepatitis of unknown aetiology,
J. Linnen et al., Molecular Cloning and Disease Association of Hepatitis G Virus: A Transfusion-Transmissible Agent,
A. Zuckerman, The new GB hepatitis viruses,
L. Altman, Three Newly Discovered Viruses May Cause Unexplained Hepatitis,
L. Altman, Newly Found Viruses May Cause Hepatitis,
T. Leary et al., Sequence and Genomic Organization of GBV-C: A novel Member of the Flaviviridae Associated With Human Non-A-E Hepetitis,
G. Caetano-Anolles et al., DNA Amplification Fingerprinting Using Arbitrary Oligonucleotide Primers,
B. Bassam, DNA amplification fingerprinting of bacteria,
G. Caetano-Anolles et al., DNA Amplification Fingerprinting Using Very Short Arbitrary Oligonucleotide Primers,
J. Welsh et al., Fingerprinting genomes using PCR with arbitrary primers*,
J. Welsh et al., Arbitrarily primed PCR fingerprinting of RNA,
J. Williams et al., DNA polymorphisms amplified by arbitrary primers are useful as genetic markers,
P. Liang et al., Differential Display of Eukaryotic Messenger RNA by Means of the Polymerase Chain Reaction,
P. Liang et al., Distribution and cloning of eukaryotic mRNAs by means of differential display: refinements and optimization,
Farci, et al., “Lack of Protective Immunity Against Reinfection with Hepatitis C Virus”,
S. Chan et al., Journal of General Virology, 73: 1131-1141 (1992).
A.S. Muerhoff et al., “Genomic Organization of GB Viruses A and B: Two New Members of the Flaviviridae Associated with GB Agent Hepatitis”,

Referenced By

Document NumberAssigneeInventorsIssue/Pub Date
US7662927 ZymoGenetics, LLC Paul O. Sheppard et al. Feb 2010
US7951531 University of Iowa Research Foundation Jack T. Stapleton et al. May 2011

Patent Family

The current document is not in a family.